Skip to main content
. 2022 Aug 10;13:967953. doi: 10.3389/fimmu.2022.967953

Table 1.

Clinical and demographical characteristics of the study population.

RRMS patients (n=457)
Age, y, median (IQR) 35 (28-44)
Female, n (%) 316 (69)
Time from symptom onset to lumbar puncture, d, median (IQR) 16 (6-34)
Follow-up time from first to last visit, y, median (IQR) 7 (4-12)
EDSS at baseline, median (range) 2 (0-7)
EDSS at censoring/last-follow-up, median (range) 2 (0-8)
RRMS patients achieving EDSS milestones, n (%):
EDSS≥3
EDSS≥6 		136 (29.7%)
37 (8.1%)
Number of MRI scans from baseline to censoring, median (IQR) 3 (3-4)
Median time to MRI scan, d, median (IQR) 186 (119-259)
T2 lesions at baseline, n (%)
• 1-9
• 10-20
• >20 		193 (42.2)
111 (24.3)
153 (33.5)
CSF specific IgG-OCB, n (%) 430 (94.1)
IgG-index>0.7, n (%) 316 (69.1)
CSF NFL (ng/L), median (IQR) 832.5 (335-2074)
DMT after first relapse, n (%)
First-line:

  • Interferon-β

  • Glatiramer-acetate

  • Dimethyl-fumarate

  • Teriflunomide

 224 (49)
36 (7.9)
59 (12.9)
11 (2.4)
Second-line

  • Natalizumab

  • Fingolimod

  • Rituximab

  • Ocrelizumab

  • Cladribine

  • Alemtuzumab

 65 (14.2)
12 (2.6)
12 (2.6)
5 (1.1)
1 (0.2)
4 (0.9)
Switched to high efficacy DMT, n (%) 200 (43.8%)

EDSS, expanded disability status scale; RRMS, relapsing remitting multiple sclerosis; CSF, cerebrospinal fluid; Ig, immunoglobulin; OCB, oligoclonal bands; DMT, disease modifying therapy.